Perioperative Management Rheumatic Diseases
Publication Date: June 20, 2022
Key Points
Key Points
- Patients with rheumatic diseases undergoing total hip arthroplasty (THA) and total knee arthroplasty (TKA) are at increased risk for periprosthetic joint infection.
- Appropriate management of antirheumatic medication in the perioperative period may provide an important opportunity to mitigate risk.
- Nonbiologic disease-modifying antirheumatic drugs may be continued throughout the perioperative period in patients with rheumatic diseases who are undergoing elective THA and TKA.
- Biologic medications should be withheld as close to 1 dosing cycle as scheduling permits prior to elective THA and TKA and restarted after evidence of wound healing, typically 14 days, for all patients with rheumatic diseases.
Treatment
Treatm...
...e 1. Medications To CONTINUE Throug...
...Medications To WITHHOLD Prior To Surgery**Having t...
...ulations Included in the GuidelineHaving troub...
...y of Recommendations (all are conditional)...
...urrent dose of methotrexate, leflunomide, hydroxy...
...current biologic agents prior to surgery...
...citinib for at least 3 days prior to surgery in...
...ntinue the current dose of mycophen...
...ld the current dose of mycophenolate mofet...
...ic therapy in patients for whom biologic th...
...inue the current daily dose of gluco...
...ee Table...